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ABSTRACT 
Background: Patients surviving an acute coronary syndrome (ACS) remain at increased risk of ischemic events 
long term. To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for 
reducing thromobotic cardiovascular diseases and stroke recurrence in Indian patients study was done. 
Methodology: A prospective, observational clinical study was carried out in the Department of General Medicine, 
of a tertiary care teaching hospital, Haldia, West Bengal. Permission from the Institutional Ethics Committee was 
obtained before starting research work.  Subjects and their accompanying family members was interviewed by pre-
structured questionnaire, and past and present prescriptions and case notes, where available, was captured and 
reviewed. Results: A total of 80 patients with CAD were enrolled for the study and equally divided in two groups to 
see efficacy and safety of dual antiplatelet therapy. The median age was 53.08 years in group 1 and 51.67 years in 
group 2; 17.5 percent and 22.5% of the patients were women in group 1 and group 2 respectively. Majority of the 
participants were male in both the groups [group 1 (82.5%) & group 2 (77.5%)]. The rate of the primary safety end 
point (severe bleeding according to the GUSTO definition) was 2.5% in the clopidogrel plus group 1 and 5% in 
group 2. The rate of moderate bleeding was 2.5% percent in the ticagrelor group and clopidogrel plus aspirin group. 
The total rate of intracranial hemorrhage was mild 7.5%, moderate 2.5% and severe 2.5% in the two treatment 
groups respectively. Conclusion: The availability of new antiplatelet agents and extended or combination therapy 
has increased the options for secondary prevention among ACS patients.  
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INTRODUCTION 
Cardiovascular diseases (CVDs) have now become 
the leading cause of mortality in India. A quarter of 
all mortality is attributable to CVD. Ischemic heart 
disease and stroke are the predominant causes and are 
responsible for >80% of CVD deaths.[1] According to 
the Global Burden of Disease study age-standardized 
estimates (2010), nearly a quarter (24.8%) of all 
deaths in India are attributable to CVD.[2] Patients 
with a history of acute coronary syndrome (ACS) 
remain at increased risk of ischemic events long 
term.[3] 
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Data from the Global Registry of Acute Coronary 
Events (GRACE) showed that more than half (53.6%) 
of ACS patients were re-hospitalized at least once 
during the 5-year follow-up period after discharge.[4] 
The mechanisms by which antiplatelet drugs interfere 
with platelet activation and aggregation involve 
targeting enzymes or receptors that are critical for the 
synthesis or action of important mediators of these 
functional responses.[5]All traditional nonsteroidal 
anti-inflammatory drugs (NSAIDs), including aspirin, 
are inhibitors of platelet COX-1. However, whereas 
aspirin permanently inactivates the enzyme, other 
NSAIDs act as reversible inhibitors. The interaction 
of ADP with one of its platelet receptors, P2Y12, can 
be blocked irreversibly by the active metabolites of 
thienopyridines (ticlopidine, clopidogrel, and 
prasugrel) or antagonized reversibly by novel drugs 
(cangrelor, ticagrelor).[6]The complementary 
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mechanisms of action of clopidogrel and aspirin have 
led to testing of the efficacy and safety of their 
combination in several high-risk settings.[7,8] The 
relative risk reduction of major vascular events 
associated with the combination of clopidogrel and 
aspirin, compared with aspirin alone, was relatively 
modest and inconsistent. The additional benefit of 
dual antiplatelet therapy versus aspirin alone was only 
a fraction of the benefit achieved by aspirin versus 
placebo in the same clinical settings[9], raising the 
possibility that the role of ADP in atherothrombosis 
may have been underestimated on the basis of 
clopidogrel trials because of incomplete and variable 
blockade of ADP-induced platelet aggregation by the 
drug.[10] To test the hypothesis that ticagrelor plus 
aspirin is safe and superior to clopidogrel plus aspirin 
for reducing thromobotic cardiovascular diseases and 
stroke recurrence in Indian patients study was done. 
METHODOLOGY  
A prospective, observational clinical study was 
carried out in the Department of General Medicine, of 
a tertiary care teaching hospital, Haldia, West Bengal. 
Permission from the Institutional Ethics Committee 
was obtained before starting research work.  Subjects 
and their accompanying family members was 
interviewed by pre-structured questionnaire, and past 
and present prescriptions and case notes, where 
available, was captured and reviewed.  All decisions 
relating to management of the patient including drugs 
and investigations was taken by the treating physician 
only. Investigator did not interfere in the management 
of patient and only observe the proceedings. Data 
regarding anti-platelet combination therapy and other 
pharmacotherapies were recorded. The prescription 
data was collected by  me by clicking the picture by 
mobile outside the medical outpatient department in a 
separate room and interviewing the CAD patients 
without the knowledge of prescriber to avoid any bias 
after taking verbal consent and after due 
administrative and Institutional Ethics Committee 
permission. 
Inclusion Criteria 
1)Subjects who was suffering from cardiovascular 
disorders and prescribed antiplatelet drug (s) at 
Medicine O.P.D. 
2)Adult patients ≥ 18 years of age and both the sexes 
was included  
3)CAD patients with co-morbidities like diabetes 
mellitus, ischemic heart diseases, congestive heart 
failure and chronic renal diseases was also be 
included in the study 
4)Those who understood the purpose of the study and 
are ready to provide information regarding their 
health status and those who signed an informed 
consent document. 
Exclusion Criteria 
1)Under 18 years of age 
2)Contraindication to antiplatelet agents like aspirin, 
ticagrelor etc. 
3)Planned surgery within 90 days 
4)Planned coronary revascularization (surgical or 
percutaneous) within 90 days 
5)Need for chronic oral anticoagulation 
6)Active bleeding or extreme-risk for major bleeding 
(e.g. active peptic ulcer disease, gastrointestinal 
pathology with a raised risk for bleeding, 
malignancies with a raised risk for bleeding) 
A total of 80 CAD patients under antiplatelet therapy 
was studied because time and facility constraints. 
Total 80 CAD patients were equally divided into 2 
groups. About 40 subjects in each group, Group 1 
[aspirin + clopidogrel] and group 2 [aspirin + 
ticagrelor] was studied. During their follow-up 
contacts at 2 months, 6 months, and 12 months, 
patients were asked to provide information regarding 
their current medications, any morbidity and their 
complications [if any]. Demographic parameters were 
analyzed by descriptive statistics.  
RESULTS
Table 1: Demographic characteristics of study participants 
Characteristic Clopidogrel plus Aspirin (N = 40) [Group 1] Ticagrelor plus Aspirin (N = 40) 
[Group 2] 
Age [yrs] 53.08±10.58 51.67±12.38 
Age groups 
<40 yrs 
40-60 yrs 
>60 yrs 
 
2 (5%) 
26 (65%) 
12 (30%) 
 
1 (2.5%) 
28 (70%) 
11 (27.5%) 
Sex [M/F] 33[ 82.5%]/7 [17.5%]; 4.71:1 31[77.5%]/ 9[22.5%]; 3.44:1 
Body mass index (Kg/m2 ) 24.9±2.3 25.7 ±1.9 
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Table 2: Clinical characteristics of study participants 
Cardiovascular risk factors 
Current smoker 
Diabetes mellitus 
Hypertension 
Dyslipidemia 
Peripheral artery disease 
Chronic renal disease 
Atrial fibrillation 
Congestive heart failure 
Previous ischemic stroke 
Previous TIA 
Previous myocardial infarction 
Prior coronary-artery bypass grafting 
 
21 (52.5%) 
11 (27.5%) 
27 (67.5) 
15 (37.5%) 
03 (7.5%) 
02 (5%) 
03 (7.5%) 
02 (5%) 
03 (7.5%) 
02 (5%) 
02 (5%) 
04 (10%) 
 
19 (47.5%) 
13 (32.5%) 
29 (72.5%) 
19 (47.5%) 
04 (10%) 
01 (2.5%) 
04 (10%) 
03 (7.5%) 
05 (12.5%) 
03 (7.5%) 
02 (5%) 
03 (7.5%) 
Median blood pressure (inter-quartile range) mm Hg*  
Systolic 
Diastolic 
 
158 (134.8–174)  
88.6 (76–102.4)  
 
156 (130.5–172.0) 
86.4 (78–96.6) 
Index event  
Unstable angina 
Non–ST-segment elevation MI 
ST-segment elevation MI 
Others  
 
14 (40%) 
11 (27.5%) 
15 (37.5%) 
- 
 
10 (25%) 
12 (30%) 
16 (40%) 
2 (5%) 
[Abbreviations: TIA, transient ischemic attack; ⁎Presented as median value with first and third quartiles] 
 
The baseline characteristics of the patients in the 
present study have been described and selected features 
are listed in [Table 1 & 2]. A total of 80 patients with 
CAD were enrolled for the study and equally divided in 
two groups to see efficacy and safety of dual 
antiplatelet therapy. The median age was 53.08 years in 
group 1 and 51.67 years in group 2; 17.5 percent and 
22.5% of the patients were women in group 1 and 
group 2 respectively. Majority of the participants were 
male in both the groups [group 1 (82.5%) & group 2 
(77.5%)]. About 26 (65%) and 28 (70%) of the present 
cases series were at the age group of 40-60 years in 
group 1 and group 2 respectively.  Average BMI was 
recorded more than 24.9±2.3 and 25.7 kg/m2 in group 1 
and group 2 respectively [Table 1].Hypertension was 
most common associated disorders in group 1 [27 
(67.5%)] and group 2 [29 (72.5%)], which was 
followed by diabetes and dyslipidemia. Good number 
of study participants was chronic smokers 21 (52.5%) 
& 19 (47.5%) in group 1 and group 2 respectively. 
There were cases of previous ischemic stroke, previous 
TIA, previous myocardial infarction, and prior 
percutaneous coronary intervention/ PCI in both the 
groups [Table 2]. Median baseline SBP blood pressure 
was noted 158 and 156 mg Hg in the study groups. 
Percentage of index events for present study enrolment 
was unstable angina (40%/25%), non–ST-segment 
elevation MI (27.5%/30%), and ST-segment elevation 
MI (37.5%/ 40%) among the study groups [Table 2].  
Table 3: Concomitant medications taken by study participants 
Characteristic Clopidogrel plus Aspirin (N = 40) Ticagrelor plus Aspirin (N = 40) 
Diuretics 07 (17.5%) 08 (20%) 
Nitrates 08 (20%) 10 (25%) 
Calcium antagonists 07 (17.5%) 07 (17.5%) 
Beta-blockers 11 (27.5%) 09 (22.5%) 
Angiotensin II–receptor blockers 09 (22.5%) 10 (25%) 
Angiotensin-converting–enzyme 
inhibitors 
10 (25%) 12 (30%) 
Other antihypertensive agents 4 (10%) 03 (7.5%) 
Statins 21 (52.5%) 19 (47.5%) 
Other lipid-lowering agents 03 (7.5%) 06 (15%) 
Anti-diabetic medications 11 (27.5%) 13 (32.5%) 
Proton pump inhibitor 32 (80%) 33 (82.5%) 
H2 blockers 06 (15%) 07 (17.5%) 
Previous anti-platelet therapy 09 (22.5%) 11 (27.5%) 
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Concomitant medications taken by the patients are shown in Table 3. Almost all the patients (aside from those who 
died or dropped out) took aspirin and the either clopidogrel/ticagrelor drug in combination. Commonly used drugs 
were proton pump inhibitors (80%, 82.5%), ACE inhibitors (25%, 30%), ARBs (22.5%, 25%), beta blockers(27.5%, 
22.5%), statins (52.5%, 47.5%) anti diabetics (27.5%, 32.5%) and nitrates (20% and 25%) in group 1 and group 2 
respectively.  
 
Table 4: Safety and efficacy outcomes among participants in two groups 
Outcome Clopidogrel plus Aspirin 
(N = 40) 
No. of patients (%) 
Ticagrelor plus Aspirin 
(N = 40) 
No. of patients (%) 
P Value 
Primary end point 
 Death from any cause 
 Death from cardiovascular causes 
 Myocardial infarction (non-fatal) 
 Stroke (fatal) 
 Ischemic stroke (nonfatal) 
 Stroke (non-fatal) 
 
            5 (12.5%) 
            3 (7.5%) 
            3 (7.5%) 
            2 (5%) 
                0 
            1 (2.5%) 
 
4 (10%) 
            3 (7.5%) 
              3 (7.5%) 
1 (2.5%) 
0 
1 (2.5%) 
 
P = 0.7251 
P = 1.0000 
P = 1.0000 
P= 0.5587 
- 
P = 1.0000 
Secondary efficacy end point 
Hospitalization for unstable angina, transient 
ischemic attack, or revascularization 
 
 
5 (12.5%) 
 
 
4 (10%) 
 
 
 
P = 0.7251 
Safety end points 
 Major bleeding 
 Moderate bleeding 
 Minor bleeding 
 
2 (5%) 
1 (2.5%) 
6 (15%) 
 
1 (2.5%) 
1 (2.5%) 
4 (10%) 
 
P= 0.5587 
P = 1.0000 
P = 0.5017 
 
Follow-up with respect to the primary efficacy end point (the first occurrence of myocardial infarction, stroke, or 
death from cardiovascular causes) was complete. With 12 months of follow-up, the rate of the primary event like 
death from any cause was 12.5% in the clopidogrel plus aspirin group and 10% in the ticagrelor plus aspirin group 
(relative risk, 1.5; 95 percent confidence interval, -12.3296% to 17.3928%; P = 0.7251) [Table 4].  
Table 5: Types of Bleeding among study participants 
Bleeding Type Mild Moderate Severe 
Conjunctival 0 0 0 
Epistaxis 1 (2.5%) 0 0 
Gastrointestinal 3 (7.5%) 1 (2.5%) 1 (2.5%) 
Gingival 0 0 0 
Hemoptysis 0 0 0 
Hematuria 0 0 0 
Intracranial 3 (7.5%) 1 (2.5%) 2 (5%) 
Intraocular 0 0 0 
Puncture site 1 (2.5%) 0 0 
Retroperitoneal 0 0 0 
Surgical 2 (5%) 0 0 
Others 0 0 0 
The rate of the primary safety end point (severe bleeding according to the GUSTO definition) was 2.5% in 
the clopidogrel plus group 1 and 5% in group 2. The rate of moderate bleeding was 2.5% percent in the ticagrelor 
group and clopidogrel plus aspirin group. The total rate of intracranial hemorrhage was mild 7.5%, moderate 2.5% 
and severe 2.5% in the two treatment groups respectively [Table 5].  
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Table 6: Percentage of patients reporting non-hemorrhagic adverse events in either group 
Characteristics Clopidogrel plus Aspirin (N = 40)[Group 
1]  
Ticagrelor plus Aspirin (N = 40)[Group 2] 
Hypersensitivity reactions  0 0 
Angioedema 0 0 
Dyspnea 3 (7.5%) 2 (5%) 
Headache 1 (2.5%) 2 (5%) 
Cough  3 (7.5%) 2 (5%) 
Dizziness  2 (5%) 3 (7.5%) 
Nausea 2 (5%) 2 (5%) 
Atrial fibrillation  0  1 (2.5%) 
New onset Hypertension  2 (5%) 2 (5%) 
Non-cardiac chest pain  2 (5%) 1 (2.5%) 
Diarrhea  1 (2.5%) 1 (2.5%) 
Back pain  0 1 (2.5%) 
Hypotension  3(7.5%) 2 (5%) 
Fatigue  3 (7.5%) 3 (7.5%) 
Bradycardia 1 (2.5%) 1 (2.5%) 
Increased serum uric acid 3 (7.5%) 1 (2.5%) 
About 7.5% and 5% of patients treated ticagrelor plus 
aspirin and clopidogrel plus aspirin developed dyspnea 
respectively. Dyspnea was usually mild (majority of 
the reported cases) to moderate in intensity which led 
to study drug discontinuation and often resolved during 
continued treatment [Table 6]. Only few cases serum 
uric acid levels increased from baseline 7.5% and 2.5% 
in group 1 and group 2. Slight increased risk of 
bradycardic events 2.5% (e.g., patients who have sick 
sinus syndrome, 2nd or 3rd degree AV block) was 
observed in the both groups [Table 6].  
DISCUSSION  
In the present study total of 80 patients with CAD were 
enrolled for the study and equally divided in two 
groups to see efficacy and safety of dual antiplatelet 
therapy. The median age was 53.08 years in group 1 
and 51.67 years in group 2; 17.5 percent and 22.5% of 
the patients were women in group 1 and group 2 
respectively. Study by Kang HJ et al (2015) showed 
Asian patients were slightly but significantly younger 
and had lower body weight and body mass index than 
non-Asian patients.[11] Study by Zhao Q et al revealed 
among 500 randomized patients (mean age, 63.6 years; 
women, 91 (18.2%), 461 (92.2%) completed the 
trial.[12]  Majority of the participants were male in both 
the groups [group 1 77.5% & group 2 82.5%]. 
Hypertension was most common associated disorders 
in group 1 [27 (67.5%)] and group 2 [29 (72.5%)], 
which was followed by diabetes and dyslipidemia. 
Several modifiable conditions (cigarette smoking, 
obesity, hypertension, hyperlipidemia), disease states 
(diabetes mellitus, renal disease), and aging are 
associated with platelet activation and represent risk 
factors for atherothrombotic complications.[13]Patients 
with acute minor ischaemic stroke and transient 
ischaemic attack are at high risk of recurrent stroke and 
cardiovascular events.[14] The Clopidogrel in High-risk 
patients with Acute Non-disabling Cerebrovascular 
Events (CHANCE) trial indicated that combined 
clopidogrel and aspirin treatment is superior to aspirin 
alone in reducing the risk of stroke, but could increase 
the risk of non-intracranial haemorrhage.[15,16] A 
genetic sub-study of the Platelet Inhibition and Patient 
Outcomes (PLATO) trial indicated that ticagrelor is 
more efficacious than clopidogrel for acute coronary 
syndromes, regardless of CYP2C19 genotype, but was 
associated with an increased risk of haemorrhage in 
patients with a history of stroke.[17] With 12 months of 
follow-up, the rate of the primary event like death from 
any cause was 12.5% in the clopidogrel plus aspirin 
group and 10% in the ticagrelor plus aspirin group 
(relative risk, 1.5; 95 percent confidence interval, -
12.3296% to 17.3928%; P = 0.7251) [Table 4]. The 
rate of the primary safety end point (severe bleeding 
according to the GUSTO definition) was 2.5% in the 
clopidogrel plus group 1 and 5% in group 2. The rate 
of moderate bleeding was 2.5% percent in the 
ticagrelor group and clopidogrel plus aspirin group. 
The total rate of intracranial hemorrhage was mild 
7.5%, moderate 2.5% and severe 2.5% in the two 
treatment groups respectively [Table 5]. About 7.5% 
and 5% of patients treated ticagrelor plus aspirin and 
clopidogrel plus aspirin developed dyspnea 
respectively. Dyspnea was usually mild (majority of 
the reported cases) to moderate in intensity which led 
to study drug discontinuation and often resolved during 
continued treatment [Table 6].As the benefits of aspirin 
in the secondary prevention of ischemic events are well 
established, guidelines recommend that a loading dose 
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of aspirin (162–325 mg) be administered as soon as 
possible following an ACS event.[17,18,19] The Acute 
Stroke or Transient Ischaemic Attack Treated With 
Aspirin or Ticagrelor and Patient Outcomes 
(SOCRATES) trial revealed a trend towards better 
efficacy in reducing the risk of vascular events in the 
ticagrelor treated group than in the aspirin group in an 
Asian subpopulation. However, limited data are 
available on the safety and efficacy of ticagrelor for the 
treatment of stroke, compared with data for clopidogrel 
on a background of aspirin in patients with acute 
stroke.[20] The Dual Antiplatelet Therapy (DAPT) study 
showed that 30 months of treatment with clopidogrel or 
prasugrel plus aspirin reduced major CV event rates 
following coronary stent placement, compared with 
12 months of treatment, although with an increased risk 
of bleeding and a suggestion of increased all-cause 
mortality (2.0 vs. 1.5%; HR 1.36, 95% CI 1.00–
1.85; p = 0.05).[21] Current US guidelines for ACS 
broadly recommend that dual antiplatelet therapy be 
continued for 12 months after the index event, followed 
by aspirin monotherapy.[18] Dual antiplatelet therapy 
(DAPT) combining aspirin and a P2Y12 receptor 
inhibitor has been consistently shown to reduce 
recurrent major adverse cardiovascular events (MACE) 
in patients with acute coronary syndrome (ACS) or 
undergoing percutaneous coronary intervention (PCI) 
for stable coronary artery disease (CAD) compared 
with aspirin monotherapy, but at the expense of an 
increased risk of major bleeding.[22] Based on limited 
evidence, 12 months duration of DAPT is currently 
recommended in patients with ACS irrespective of 
their management strategy, but large ongoing 
randomised trials are currently assessing the efficacy 
and safety of a short-term DAPT strategy (3–6 months) 
for patients with ACS undergoing PCI with newer 
generation DES. Finally, several ongoing, large-scale, 
randomised trials are challenging the current concept of 
DAPT by investigating P2Y12 receptor inhibitors as 
single antiplatelet therapy and may potentially shift the 
paradigm of antiplatelet therapy after PCI in the near 
future[22].Wang Yilong et al study revealed the 
primary safety outcome (PLATO major haemorrhagic 
event) occurred in five patients (1.5%) in the 
ticagrelor/aspirin group and four (1.2%) in the 
clopidogrel/aspirin group (hazard ratio 1.27; 95% 
confidence interval 0.34 to 4.72).[23] Three patients 
(0.9%) in the ticagrelor/aspirin group and two (0.6%) 
in the clopidogrel/aspirin group had intracranial 
haemorrhage. However, the rate of any haemorrhagic 
events occurring was higher in the ticagrelor/aspirin 
group (22.3%) than in the clopidogrel/aspirin group 
(14.2%; 1.65, 1.15 to 2.37). All of the proportional 
hazard assumptions were met (P=0.99 for major 
haemorrhagic event and P=0.82 for any haemorrhagic 
events). Vranckx P et al study revealed that ticagrelor 
in combination with aspirin for 1 month followed by 
ticagrelor alone for 23 months was not superior to 12 
months of standard dual antiplatelet therapy followed 
by 12 months of aspirin alone in the prevention of all-
cause mortality or new Q-wave myocardial infarction 2 
years after percutaneous coronary intervention.[24] 
CONCLUSION 
In this study of patients with established 
atherothrombotic disease or at high risk for such 
disease, there was slightly higher but non-significant 
benefit associated with ticagrelor plus aspirin as 
compared with clopidogrel plus aspirin in reducing the 
incidence of the primary end point of myocardial 
infarction, stroke, or death from cardiovascular causes. 
There was a moderate, though not significant, benefit 
in reducing the secondary composite end point of 
myocardial infarction, stroke, and death from 
cardiovascular causes, or hospitalization for unstable 
angina, transient ischemic attack, or revascularization. 
REFERENCES  
1. Prabhakaran D, Jeemon P, RoyA. Cardiovascular 
Diseases in India: Current Epidemiology and Future 
Directions. Circulation. 2016 ;133(16):1605-20.  
2. Institute of Health Metrics and Evaluation. GBD 
Compare 2010. http://vizhub.healthdata.org/gbd-
compare/. Accessed September 30, 2019 
3. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto 
S, Mahoney EM, et al. Comparative determinants of 
4-year cardiovascular event rates in stable outpatients 
at risk of or with atherothrombosis JAMA.  
2010;304(12):1350–1357. 
4. Fox KA, Carruthers KF, Dunbar DR, Graham C, 
Manning JR, De Raedt H, et al. Underestimated and 
under-recognized: the late consequences of acute 
coronary syndrome (GRACE UK-Belgian Study) Eur 
Heart J. 2010;31(22):2755–2764. 
5. Patrono C, Baigent C, Hirsh J, et al. Antiplatelet 
drugs: American College of Chest Physicians 
evidence-based clinical practice guidelines (eighth 
edition). Chest .2008;133:199S–233S. 
6. Weitz JI, Hirsh J, Samama MM. 2008. New 
antithrombotic drugs: American College of Chest 
Physicians evidence-based clinical practice 
guidelines (eighth edition). Chest 133:234S–56S. 
7. Bhatt DL, Fox KA, Hacke W. Clopidogrel and 
aspirin versus aspirin alone for the prevention of 
atherothrombotic events. N. Engl. J. Med. 
2006;354:1706–1740. 
 
Asian Pac. J. Health Sci., 2020; 7(1):97-103                                            e-ISSN: 2349-0659, p-ISSN: 2350-0964 
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
 Verma and Prasad         Asian Pacific Journal of Health Sciences, 2020;7(1):97-103                  Page 103 
www.apjhs.com       
 
8. The ACTIVE investigators. 2009. Effect of 
clopidogrel added to aspirin in patients with atrial 
fibrillation. N. Engl. J. Med. 360:2066–78. 
9. Antithrombotic Trialists Collaboration. Collaborative 
meta-analysis of randomised trials of antiplatelet 
therapy for prevention of death, myocardial 
infarction, and stroke in high-risk patients. 
BMJ.2002; 324:71–86. 
10. Dav`ı G, Patrono C. 2007. Platelet activation and 
atherothrombosis. N. Engl. J. Med. 357:2482–94). 
11. Kang HJ, Clare RM, Gao R, Held C, Himmelmann 
A, James SK, et al.  Ticagrelor  versus 
 clopidogrel in Asian patients with acute coronary sy
ndrome: A retrospective analysis from the 
 Platelet Inhibition and Patient Outcomes (PLATO) T
rial. Am Heart J. 2015; 169(6):899-905. 
12. Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, et al. 
Effect of  Ticagrelor  Plus Aspirin,  Tica 
grelor Alone, or Aspirin Alone on Saphenous 
Vein Graft Patency 1 Year After Coronary Artery 
Bypass Grafting: A Randomized Clinical Trial. 
JAMA. 2018 ; 319(16):1677-1686. 
13. Gaudino M, Antoniades C, Benedetto U, et al; 
ATLANTIC (Arterial Grafting International 
Consortium) Alliance. Mechanisms, consequences, 
and prevention of coronary graft failure. Circulation. 
2017;136(18):1749-1764. 
14. Amarenco P, Lavallée PC, Labreuche J, et al. TIA 
registry.org Investigators. One-year risk of stroke 
after transient ischemic attack or minor stroke. N 
Engl J Med2016; 374:1533-42.  
15. Wang Y, Wang Y, Zhao X, et al., CHANCE 
Investigators. Clopidogrel with aspirin in acute minor 
stroke or transient ischemic attack. N Engl J 
Med2013; 369:11-16. 
16. Wenaweser P, Dörffler-Melly J, Imboden K, et al. 
Stent thrombosis is associated with an impaired 
response to antiplatelet therapy. J Am Coll 
Cardiol2005; 45:1748-52.  
17. Wallentin L, James S, Storey RF, Armstrong M,  
Barratt BJ,  Horrow J, et al; PLATO investigators. 
Effect of CYP2C19 and ABCB1 single nucleotide 
polymorphisms on outcomes of treatment with 
ticagrelor versus clopidogrel for acute coronary 
syndromes: a genetic substudy of the PLATO trial. 
Lancet. 2010;376(9749):1320-8.  
18.  Amsterdam EA, Wenger NK, Brindis RG, et al. 
2014 AHA/ACC guideline for the management of 
patients with non-ST-elevation acute coronary 
syndromes: a report of the American College of 
Cardiology/American Heart Association Task Force 
on Practice Guidelines. Circulation. 
2014;130(25):e344-426. 
19. O'Gara PT, Kushner FG, Ascheim DD, et al. 
ACCF/AHA guideline for the management of ST-
elevation myocardial infarction: a report of the 
American College of Cardiology Foundation/ 
American Heart Association Task Force on Practice 
Guidelines. J Am Coll Cardiol. 2013; 61(4):e78-140. 
20. Amarenco P, Albers GW, Denison H, et al. 
SOCRATES Steering Committee and Investigators. 
Efficacy and safety of ticagrelor versus aspirin in 
acute stroke or transient ischaemic attack of 
atherosclerotic origin: a subgroup analysis of 
SOCRATES, a randomised, double-blind, controlled 
trial. Lancet Neurol. 2017;16:301-10.  
21. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, 
Cutlip DE, Steg PG, et al. Twelve or 30 months of 
dual antiplatelet therapy after drug-eluting stents. N 
Engl J Med. 2014;371(23):2155–2166. 
22. Degrauwe S, Pilgrim T, Aminian A, Noble S, Meier 
P, Iglesias JF. Dual antiplatelet therapy for secondary 
prevention of coronary artery disease. Open Heart. 
2017;4(2):e000651. 
23. Wang Yilong, Chen Weiqi, Lin Yi, Meng Xia, Chen 
Guohua, Wang Zhimin et al. Ticagrelor plus aspirin 
versus clopidogrel plus aspirin for platelet reactivity 
in patients with minor stroke or transient ischaemic 
attack: open label, blinded endpoint, randomised 
controlled phase II trial  BMJ 2019; 365 :l2211 
24. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg 
PG, Heg D, et al; Global leaders Investigators. 
Ticagrelor plus aspirin for 1 month, followed by 
ticagrelor monotherapy for 23 months vs aspirin plus 
clopidogrel or ticagrelor for 12 months, followed by 
aspirin monotherapy for 12 months after implantation 
of a drug-eluting stent: a multicentre, open-label, 
randomised superiority trial. Lancet. 2018 
;392(10151):940-949.  
 How to cite this Article: Verma AK, Prasad MK. Evaluation of 
efficacy and safety of antiplatelet combinations [Clopidogrel plus 
Aspirin versus Ticagrelor plus Aspirin] in patient with the thromobotic 
cardiovascular diseases – An observational study. Asian Pac. J. Health 
Sci., 2020; 7(1):97-103.  
Source of Support: Nil, Conflict of Interest: None declared. 
 
 
. Antibacterial and antifungal evaluation of some 
chalcogen bearing ligands, their transition and non-
transition metal complexes. Indian J. Pharm. Biol. 
Res.2015; 3(3):1-6. 
 
 
 
 
